BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35806325)

  • 21. Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?
    Chun SG; Choe KS; Iyengar P; Yordy JS; Timmerman RD
    Cancer Biol Ther; 2012 Dec; 13(14):1376-83. PubMed ID: 22986231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement.
    Kwon JH; Kim KJ; Sung JH; Suh KJ; Lee JY; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Bang SM; Kim S; Yoon SS; Lee JS
    Cells; 2019 Nov; 8(12):. PubMed ID: 31795298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
    Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
    Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays.
    Li T; Maus MK; Desai SJ; Beckett LA; Stephens C; Huang E; Hsiang J; Zeger G; Danenberg KD; Astrow SH; Gandara DR
    J Thorac Oncol; 2014 Jan; 9(1):18-25. PubMed ID: 24346090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation.
    Tufman AL; Edelmann M; Gamarra F; Reu S; Borgmeier A; Schrödl K; Zauber R; Müller-Lisse U; Huber RM
    J Thorac Oncol; 2014 Jan; 9(1):109-13. PubMed ID: 24346098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical Advanced in Early-stage ALK-positive Non-small Cell Lung Cancer Patients].
    Gao Q; Jiang X; Huang C
    Zhongguo Fei Ai Za Zhi; 2017 Feb; 20(2):124-129. PubMed ID: 28228224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel KIF5B-ALK variant in nonsmall cell lung cancer.
    Wong DW; Leung EL; Wong SK; Tin VP; Sihoe AD; Cheng LC; Au JS; Chung LP; Wong MP
    Cancer; 2011 Jun; 117(12):2709-18. PubMed ID: 21656749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer.
    Cui S; Zhang W; Xiong L; Pan F; Niu Y; Chu T; Wang H; Zhao Y; Jiang L
    Oncotarget; 2017 Jan; 8(2):2771-2780. PubMed ID: 27926526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
    Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
    J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
    Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
    J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TaqMan based real time PCR assay targeting EML4-ALK fusion transcripts in NSCLC.
    Robesova B; Bajerova M; Liskova K; Skrickova J; Tomiskova M; Pospisilova S; Mayer J; Dvorakova D
    Lung Cancer; 2014 Jul; 85(1):25-30. PubMed ID: 24792336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
    Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
    Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer.
    Sakai K; Okamoto I; Takezawa K; Hirashima T; Kaneda H; Takeda M; Matsumoto K; Kimura H; Fujita Y; Nakagawa K; Arao T; Nishio K
    J Thorac Oncol; 2012 May; 7(5):913-8. PubMed ID: 22722791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
    J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
    Takeuchi K; Choi YL; Soda M; Inamura K; Togashi Y; Hatano S; Enomoto M; Takada S; Yamashita Y; Satoh Y; Okumura S; Nakagawa K; Ishikawa Y; Mano H
    Clin Cancer Res; 2008 Oct; 14(20):6618-24. PubMed ID: 18927303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of anaplastic lymphoma kinase overexpression and the EML4-ALK fusion gene in non-small cell lung cancer by immunohistochemical study.
    Chen TD; Chang IC; Liu HP; Wu YC; Wang CL; Chen YT; Chen YR; Huang SF
    Chang Gung Med J; 2012; 35(4):309-17. PubMed ID: 22913857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
    Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
    Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
    Shaw AT; Yeap BY; Mino-Kenudson M; Digumarthy SR; Costa DB; Heist RS; Solomon B; Stubbs H; Admane S; McDermott U; Settleman J; Kobayashi S; Mark EJ; Rodig SJ; Chirieac LR; Kwak EL; Lynch TJ; Iafrate AJ
    J Clin Oncol; 2009 Sep; 27(26):4247-53. PubMed ID: 19667264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
    J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.